X4 Pharmaceuticals, Inc. XFOR
Set alert
3.30 USD -0.06 -1.64%
As of Nov 3, 12:53 PM ET
3.26 Day range 3.42
2.43 52-week range 4.83
- YTD
- -17.63%
- 1 year
- -19.44%
- Open
- 3.37
- Prev close
- 3.35
- Mkt cap
- 327.18M
- Vol
- 165.61K
- Avg vol
- 861.16K
- EPS
- 0.02
- P/E
- 165.00
- Div yield
- 0.00%
More statistics
- Low
- 3.26
- High
- 3.42
- Forward P/E
- -1.23
- Beta
- 0.39
- Short ratio
- 8.64
- Inst. own
- 67.66%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 0.50158
- 200-d avg
- 0.79766
- 1y target
- 3.05
3M chart
Signals (17)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Nov 3, 2026 | 3 hours ago |
| SMA: Bullish | Oct 29, 2026 | 5 days ago |
| SMA: Bullish | Oct 22, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 16, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 14, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 13, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 9, 2026 | 3 weeks ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| RSI: Oversold | Sep 10, 2026 | 1 month ago |
| RSI: Oversold | Sep 8, 2026 | 1 month ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 19, 2026 | 2 months ago |
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 3.05 -7.5% downside
Now 3.30
- Target (low)
- 1.50
- Target (mean)
- 3.05
- Target (high)
- 4.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.1575 | -0.17 – -0.13 | -0.10 | -57.5% | 1.06M | 0.0% | 5 |
| Next quarter | -0.14667 | -0.17 – -0.12 | -0.26 | +43.6% | 2.53M | 0.0% | 3 |
| Current year | -0.1525 | -0.16 – -0.14 | -0.57 | +73.3% | 2.19M | 0.0% | 4 |
| Next year | -0.486 | -0.70 – -0.09 | -0.1525 | -218.7% | 16.55M | +654.6% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 14, 2024 | Stifel | Maintained | Buy | Buy |
| Jun 28, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 31, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Apr 30, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 22, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Dec 12, 2023 | B. Riley Securities | Downgrade | Buy | Neutral |
| Aug 11, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 17, 2023 | Stifel | Maintained | Buy | Buy |
| May 5, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Apr 10, 2023 | B. Riley Securities | Maintained | — | Buy |
| Mar 24, 2023 | Oppenheimer | Maintained | — | Outperform |
| Mar 22, 2023 | Cantor Fitzgerald | Maintained | — | Overweight |
| Mar 22, 2023 | HC Wainwright & Co. | Maintained | — | Buy |
| Dec 22, 2022 | Cantor Fitzgerald | Initiated | — | Overweight |
| Dec 12, 2022 | Piper Sandler | Initiated | — | Overweight |
| Nov 30, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| May 19, 2022 | B. Riley Securities | Maintained | — | Buy |
| May 13, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Apr 5, 2022 | Canaccord Genuity | Maintained | — | Buy |
| Dec 14, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Dec 17, 2020 | Brookline Capital | Initiated | — | Buy |
| Nov 9, 2020 | Canaccord Genuity | Maintained | — | Buy |
| May 8, 2020 | HC Wainwright & Co. | Reiterated | — | Outperform |
| May 8, 2020 | B. Riley Securities | Maintained | — | Buy |
| Mar 26, 2020 | Citigroup | Maintained | — | Buy |
| Mar 13, 2020 | B. Riley Securities | Maintained | — | Buy |
| Jan 7, 2020 | HC Wainwright & Co. | Initiated | — | Buy |
| Dec 23, 2019 | Oppenheimer | Initiated | — | Outperform |
| Dec 18, 2019 | Roth Capital | Initiated | — | Buy |